Young And HIV Positive In China: A Snapshot
This article was originally published in PharmAsia News
The number of young students who are infected with HIV/AIDS in China has seen a nearly 30% jump, in a country where the issue used to be a social taboo. New treatments for HIV/AIDS will be prioritized for fast-track review and approval, regulators have said.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.